Endra Life Sciences (NDRA) Stock News

ENDRA Life Sciences (NASDAQ: NDRA) reported multi-site clinical validation of its TAEUS® Liver device for steatotic liver disease assessment. In 64 patients across U.S. and Canada, TAEUS Liver showed strong concordance with MRI-PDFF and high reproducibility across operators and sites.

• Correlation to MRI-PDFF: r=0.90 (combined cohort)
• Diagnostic accuracy: AUROC 0.95–0.99 at key thresholds
• Mean error: ~3%, ~90% of measurements within ~5% of MRI
• Reproducibility: ICC=0.89 across operators; performance independent of BMI/body habitus
• Economics: anticipated per-scan cost under $200, less than 8% of a typical MRI-PDFF exam

According to ENDRA, these results support the planned regulatory pathway and suggest potential use in routine clinical practice and pharmaceutical trials.

ENDRA Life Sciences (NASDAQ: NDRA) reported Q4 and full-year 2025 results and a business update on March 31, 2026. The Board initiated an evaluation of strategic alternatives on March 25, 2026. Clinical milestones include TAEUS Liver feasibility results (Pearson r=0.89) and repeatability (ICC 0.89, SEM 3.3%).

Financials: 2025 operating expenses were $5.8M (down from $10.8M in 2024), net loss $7.0M (2024: $11.5M), cash and equivalents $762,000, and $2.0M held in a Digital Asset Treasury.

ENDRA Life Sciences (Nasdaq: NDRA) said its Board of Directors has launched a formal review of strategic alternatives to maximize shareholder value, including possible investments, mergers, collaborations, asset sales, or a sale of the company.

The Board engaged Lucid Capital Management as financial advisor and K&L Gates as legal counsel and said operations will continue while no timetable has been set for completion.

ENDRA (NASDAQ: NDRA) reported that its TAEUS Liver device achieved an intraclass correlation coefficient (ICC) of 0.89 and a standard error of measurement (SEM) of 3.3% in a clinical consistency study involving 14 subjects and 56 measurements.

Results indicate good-to-excellent intra-user repeatability and inter-user reproducibility, suggesting the device can deliver MRI-level quantitative liver fat consistency at the point of care and lower cost for monitoring MASLD.

ENDRA (NASDAQ: NDRA) reported 2025 feasibility results showing its TAEUS thermo-acoustic fat fraction (TAFF) measurement closely tracks MRI-PDFF at clinical liver fat fraction thresholds used for MASLD/MASH trials.

Key data from 40 subjects: 12–17% LFF average PPV 100%, NPV 94%, Accuracy 95%; 20–22% LFF average PPV 90%, NPV 94%, Accuracy 94%. TAEUS aims to offer point-of-care scans at under $200 vs MRI exams often >$2,500, supporting frequent monitoring and potential trial cost reductions. A second feasibility study is underway and ENDRA plans FDA engagement in 2026 on a pivotal study design.

ENDRA Life Sciences (NASDAQ: NDRA) reported preliminary results from a single-site feasibility study showing its 2025 optimized TAEUS Liver device quantifies liver fat fraction closely aligned with MRI‑PDFF, the imaging gold standard.

Key metrics: 40 subjects (BMI 21–47), Deming regression slope=1 and intercept=0 within 95% CIs, Pearson r=0.89, >90% of subjects within a 5% error margin and average error ~3%. ENDRA plans FDA pre‑submission meetings and a pivotal study; a second feasibility study is underway in Canada.

ENDRA Life Sciences (Nasdaq: NDRA) reported business and Q3 2025 results on November 17, 2025, highlighting financing, balance-sheet actions and clinical progress for its TAEUS® liver imaging device.

Key facts: the company closed a PIPE that generated gross proceeds of approximately $4.9 million on October 23, 2025, with potential additional proceeds of $9.5 million via warrant exercises; regained Nasdaq compliance with Rule 5550(b)(1); reduced cash burn from operations by 30% to $1.2 million in Q3 2025; Q3 operating expenses were $1.4 million versus $1.5 million a year ago; cash and equivalents were $0.8 million at September 30, 2025; and the company completed a single-site clinical feasibility study of the redesigned TAEUS® device with results to be released soon.

ENDRA Life Sciences (Nasdaq: NDRA) has commenced staking its holdings of HYPE, the native token of the Hyperliquid ecosystem, as part of a digital asset treasury strategy announced on November 13, 2025. Guided by ARCA Investment Management and using institutional custody and staking services from Anchorage Digital, ENDRA deployed its HYPE position into a secure staking solution following its initial HYPE investment on October 23, 2025.

The company says staking will generate network rewards, support Hyperliquid network security and decentralization, and provide strategic access to potential governance and DeFi opportunities while aligning with its disciplined treasury management approach.

ENDRA Life Sciences (Nasdaq: NDRA) closed a private placement financing that generated gross proceeds of approximately $4.9 million with potential for up to an additional $9.5 million from warrant exercises. Concurrently, the company launched a digital asset treasury strategy and acquired 78,863.1 HYPE tokens, valued at approximately $3.0 million as of October 21, 2025.

The DAT strategy targets long-term token exposure plus active yield techniques (options overlays, staking, DeFi participation) with trade‑ and portfolio‑level risk controls, aiming to grow tokens‑per‑share, generate reinvestable income, and create optionality for crypto‑related M&A and capital activities. Lucid Capital Markets acted as sole placement agent.